Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 112 articles:
HTML format
Text format



Single Articles


    July 2017
  1. TAN DSW
    Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade.
    J Clin Oncol. 2017 Jul 17:JCO2017736215. doi: 10.1200/JCO.2017.73.6215.
    PubMed     Text format    


  2. FARAGO AF, Piotrowska Z, Sequist LV
    Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma.
    J Clin Oncol. 2017 Jul 10:JCO2017735696. doi: 10.1200/JCO.2017.73.5696.
    PubMed     Text format    


  3. BENDZSAK AM, Baxter NN, Darling GE, Austin PC, et al
    Regionalization and Outcomes of Lung Cancer Surgery in Ontario, Canada.
    J Clin Oncol. 2017 Jul 6:JCO2016698076. doi: 10.1200/JCO.2016.69.8076.
    PubMed     Text format     Abstract available


    June 2017
  4. HAN SS, Rivera GA, Tammemagi MC, Plevritis SK, et al
    Risk Stratification for Second Primary Lung Cancer.
    J Clin Oncol. 2017 Jun 23:JCO2017724203. doi: 10.1200/JCO.2017.72.4203.
    PubMed     Text format     Abstract available


  5. PETERS S, Gettinger S, Johnson ML, Janne PA, et al
    Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
    J Clin Oncol. 2017 Jun 13:JCO2016719476. doi: 10.1200/JCO.2016.71.9476.
    PubMed     Text format     Abstract available


  6. JALAL SI, Lavin P, Lo G, Lebel F, et al
    Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE).
    J Clin Oncol. 2017 Jun 12:JCO2016717454. doi: 10.1200/JCO.2016.71.7454.
    PubMed     Text format     Abstract available


    May 2017
  7. HEIST RS, Guarino MJ, Masters G, Purcell WT, et al
    Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
    J Clin Oncol. 2017 May 26:JCO2016721894. doi: 10.1200/JCO.2016.72.1894.
    PubMed     Text format     Abstract available


  8. EBERHARDT WEE
    How Should We Choose the Best Therapy for Elderly Patients With Stage III Non-Small-Cell Lung Cancer?
    J Clin Oncol. 2017 May 24:JCO2017729053. doi: 10.1200/JCO.2017.72.9053.
    PubMed     Text format    


  9. LIM SM, Kim HR, Lee JS, Lee KH, et al
    Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
    J Clin Oncol. 2017 May 18:JCO2016713701. doi: 10.1200/JCO.2016.71.3701.
    PubMed     Text format     Abstract available


  10. OU SI
    Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 May 11:JCO2017731323. doi: 10.1200/JCO.2017.73.1323.
    PubMed     Text format    


  11. STINCHCOMBE TE, Zhang Y, Vokes EE, Schiller JH, et al
    Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.
    J Clin Oncol. 2017 May 11:JCO2016714758. doi: 10.1200/JCO.2016.71.4758.
    PubMed     Text format     Abstract available


  12. EDELMAN MJ, Wang X, Hodgson L, Cheney RT, et al
    Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
    J Clin Oncol. 2017 May 10:JCO2016713743. doi: 10.1200/JCO.2016.71.3743.
    PubMed     Text format     Abstract available


  13. POPAT S
    Do Statins Improve Survival in Small-Cell Lung Cancer?
    J Clin Oncol. 2017;35:1497-1498.
    PubMed     Text format    


  14. CHALMERS A, Akerley W
    Retrospective, Multi-Institutional Analysis of Sequential Treatment of Brain Metastases in Treatment-Naive, Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer Should Not Define the Standard of Practice.
    J Clin Oncol. 2017 May 8:JCO2017727255. doi: 10.1200/JCO.2017.72.7255.
    PubMed     Text format    


  15. KIM DW, Tiseo M, Ahn MJ, Reckamp KL, et al
    Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
    J Clin Oncol. 2017 May 5:JCO2016715904. doi: 10.1200/JCO.2016.71.5904.
    PubMed     Text format     Abstract available


    April 2017
  16. SHEPHERD FA, Lacas B, Le Teuff G, Hainaut P, et al
    Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
    J Clin Oncol. 2017 Apr 28:JCO2016712893. doi: 10.1200/JCO.2016.71.2893.
    PubMed     Text format     Abstract available


  17. ZHONG WZ, Liu SY, Wu YL
    Numbers or Stations: From Systematic Sampling to Individualized Lymph Node Dissection in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017;35:1143-1145.
    PubMed     Text format    


    March 2017
  18. DESS RT, Sun Y, Matuszak MM, Sun G, et al
    Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Mar 16:JCO2016716142. doi: 10.1200/JCO.2016.71.6142.
    PubMed     Text format     Abstract available


  19. TAMURA T, Kiura K, Seto T, Nakagawa K, et al
    Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.
    J Clin Oncol. 2017 Mar 15:JCO2016705749. doi: 10.1200/JCO.2016.70.5749.
    PubMed     Text format     Abstract available


    February 2017
  20. SECKL MJ, Ottensmeier CH, Cullen M, Schmid P, et al
    Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).
    J Clin Oncol. 2017 Feb 27:JCO2016697391. doi: 10.1200/JCO.2016.69.7391.
    PubMed     Text format     Abstract available


  21. YANG JC, Ahn MJ, Kim DW, Ramalingam SS, et al
    Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
    J Clin Oncol. 2017 Feb 21:JCO2016703223. doi: 10.1200/JCO.2016.70.3223.
    PubMed     Text format     Abstract available


  22. RUSTHOVEN CG, Palma DA, Senan S, Kavanagh BD, et al
    The Head Start Effect: Will Acute and Delayed Postoperative Mortality Lead to Improved Survival with Stereotactic Body Radiation Therapy for Operable Stage I Non-Small-Cell Lung Cancer?
    J Clin Oncol. 2017 Feb 21:JCO2016720003. doi: 10.1200/JCO.2016.72.0003.
    PubMed     Text format    


  23. NEAL JW, Wakelee HA
    Elusive Target of Angiogenesis in Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Feb 6:JCO2016716084. doi: 10.1200/JCO.2016.71.6084.
    PubMed     Text format    


    January 2017
  24. TISEO M, Boni L, Ambrosio F, Camerini A, et al
    Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.
    J Clin Oncol. 2017 Jan 30:JCO2016694844. doi: 10.1200/JCO.2016.69.4844.
    PubMed     Text format     Abstract available


  25. MARCUS MW, Field JK
    Is Bootstrapping Sufficient for Validating a Risk Model for Selection of Participants for a Lung Cancer Screening Program?
    J Clin Oncol. 2017 Jan 23:JCO2016713214. doi: 10.1200/JCO.2016.71.3214.
    PubMed     Text format    


  26. SIMONE CB 2ND
    New Era in Radiation Oncology for Lung Cancer: Recognizing the Importance of Cardiac Irradiation.
    J Clin Oncol. 2017 Jan 23:JCO2016715581. doi: 10.1200/JCO.2016.71.5581.
    PubMed     Text format    


  27. MAGNUSON WJ, Lester-Coll NH, Wu AJ, Yang TJ, et al
    Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naive Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    J Clin Oncol. 2017 Jan 23:JCO2016697144. doi: 10.1200/JCO.2016.69.7144.
    PubMed     Text format     Abstract available


  28. ZHOU L, Deng L, Lu Y
    Epidermal Growth Factor Receptor Mutations in Non-Small-Cell Lung Cancer With Brain Metastasis: Can Up-Front Radiation Therapy Be Deferred or Withheld?
    J Clin Oncol. 2017 Jan 23:JCO2016715706. doi: 10.1200/JCO.2016.71.5706.
    PubMed     Text format    


  29. WANG K, Eblan MJ, Deal AM, Lipner M, et al
    Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.
    J Clin Oncol. 2017 Jan 23:JCO2016700229. doi: 10.1200/JCO.2016.70.0229.
    PubMed     Text format     Abstract available


  30. EGUCHI T, Bains S, Lee MC, Tan KS, et al
    Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Patients With Stage I Non-Small-Cell Lung Cancer: A Competing Risks Analysis.
    J Clin Oncol. 2017;35:281-290.
    PubMed     Text format     Abstract available


  31. MULLER DC, Johansson M, Brennan P
    Lung Cancer Risk Prediction Model Incorporating Lung Function: Development and Validation in the UK Biobank Prospective Cohort Study.
    J Clin Oncol. 2017 Jan 17:JCO2016692467. doi: 10.1200/JCO.2016.69.2467.
    PubMed     Text format     Abstract available


  32. BUNN PA JR
    Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016.
    J Clin Oncol. 2017;35:243-252.
    PubMed     Text format    


  33. BALL D, Mac Manus M, Siva S, Plumridge N, et al
    Routine Use of Intensity-Modulated Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Is Neither Choosing Wisely Nor Personalized Medicine.
    J Clin Oncol. 2017 Jan 9:JCO2016713156.
    PubMed     Text format    


  34. BRADLEY CJ, Yabroff KR, Mariotto AB, Zeruto C, et al
    Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011).
    J Clin Oncol. 2017 Jan 3:JCO2016694166.
    PubMed     Text format     Abstract available


  35. WANG TH, Hu YW, Hu YW
    Benefit of Adjuvant Therapy in Postoperative Early-Stage Small-Cell Lung Cancer: Is There Sufficient Evidence?
    J Clin Oncol. 2017;35:117.
    PubMed     Text format    


  36. CHUN SG, Hu C, Choy H, Komaki RU, et al
    Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
    J Clin Oncol. 2017;35:56-62.
    PubMed     Text format     Abstract available


    December 2016
  37. MOLITORIS JK, Edelman MJ, Regine WF, Feigenberg SJ, et al
    Whole-Brain Radiation in the Treatment of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Dec 28:JCO2016697227.
    PubMed     Text format    


  38. LIANG W, He J, Shen Y, Shen J, et al
    Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non-Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry.
    J Clin Oncol. 2016 Dec 28:JCO2016675140.
    PubMed     Text format     Abstract available


  39. OTA A, Gyawali B, Matsuoka A, Ando Y, et al
    Unconvincing Benefit of Combination Therapy With Gefitinib and Pemetrexed in Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Dec 5:JCO2016704148.
    PubMed     Text format    


  40. KIM YH
    Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    J Clin Oncol. 2016 Dec 5:JCO2016702472.
    PubMed     Text format    


  41. JANSEN F, Krebber AM, Coupe VM, Cuijpers P, et al
    Cost-Utility of Stepped Care Targeting Psychological Distress in Patients With Head and Neck or Lung Cancer.
    J Clin Oncol. 2016 Dec 5:JCO2016688739.
    PubMed     Text format     Abstract available


  42. GADGEEL SM, Shaw AT, Govindan R, Gandhi L, et al
    Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016;34:4079-4085.
    PubMed     Text format     Abstract available


  43. WARDAK Z, Choy H
    Improving Treatment Options for Brain Metastases From ALK-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016;34:4064-4065.
    PubMed     Text format    


    November 2016
  44. WIDDER J, Van De Wauwer C, Langendijk JA
    Lobectomy or Sublobectomy for Small Non-Small-Cell Lung Cancer: The Question Remains.
    J Clin Oncol. 2016 Nov 28:JCO2016700872.
    PubMed     Text format    


  45. LEE SM, Falzon M, Blackhall F, Spicer J, et al
    Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).
    J Clin Oncol. 2016 Nov 28:JCO2016681841.
    PubMed     Text format     Abstract available


  46. POSTEL-VINAY S, Soria JC
    ERCC1 as Predictor of Platinum Benefit in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Nov 28:JCO2016705053.
    PubMed     Text format    


  47. ROSENZWEIG KE, Gomez JE
    Concurrent Chemotherapy and Radiation Therapy for Inoperable Locally Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Nov 21:JCO2016699678.
    PubMed     Text format     Abstract available


  48. SULLIVAN DR, Forsberg CW, Ganzini L, Au DH, et al
    Longitudinal Changes in Depression Symptoms and Survival Among Patients With Lung Cancer: A National Cohort Assessment.
    J Clin Oncol. 2016;34:3984-3991.
    PubMed     Text format     Abstract available


    September 2016
  49. RIESS JW, Lara PN Jr, Gandara DR
    Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Sep 6. pii: JCO690040.
    PubMed     Text format    


    August 2016
  50. GAJRA A, Loh KP, Hurria A, Muss H, et al
    Comprehensive Geriatric Assessment-Guided Therapy Does Improve Outcomes of Older Patients With Advanced Lung Cancer.
    J Clin Oncol. 2016 Aug 22. pii: JCO675926.
    PubMed     Text format    


  51. SINGH N, Prasad KT
    A Cola to Improve My EGFR TKI Absorption in Metastatic Non-Small-Cell Lung Cancer? No, Thank You, I Prefer Lemonade or Orange Juice Instead.
    J Clin Oncol. 2016 Aug 22. pii: JCO687426.
    PubMed     Text format    


  52. CHENG Y, Murakami H, Yang PC, He J, et al
    Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    J Clin Oncol. 2016 Aug 9. pii: JCO669218.
    PubMed     Text format     Abstract available


  53. PAPADIMITRAKOPOULOU V, Lee JJ, Wistuba II, Tsao AS, et al
    The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Aug 1. pii: JCO660084.
    PubMed     Text format     Abstract available


    July 2016
  54. RECK M, Luft A, Szczesna A, Havel L, et al
    Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jul 25. pii: JCO676601.
    PubMed     Text format     Abstract available


  55. DAMMEIJER F, Lievense LA, Veerman GD, Hoogsteden HC, et al
    The Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2016 Jul 18. pii: JCO663955.
    PubMed     Text format     Abstract available


  56. ROSELL R, Karachaliou N
    Implications of Blood-Based T790M Genotyping and Beyond in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jul 18. pii: JCO683458.
    PubMed     Text format    


  57. CRINO L, Ahn MJ, De Marinis F, Groen HJ, et al
    Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
    J Clin Oncol. 2016 Jul 18. pii: JCO655936.
    PubMed     Text format     Abstract available


  58. GAINOR JF
    Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jul 5. pii: JCO681205.
    PubMed     Text format    


    June 2016
  59. GETTINGER S, Rizvi NA, Chow LQ, Borghaei H, et al
    Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jun 27. pii: JCO669929.
    PubMed     Text format     Abstract available


  60. YOSHIDA T, Oya Y, Tanaka K, Shimizu J, et al
    Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jun 27. pii: JCO658732.
    PubMed     Text format     Abstract available


  61. RIZVI NA, Hellmann MD, Brahmer JR, Juergens RA, et al
    Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jun 27. pii: JCO669861.
    PubMed     Text format     Abstract available


  62. OXNARD GR, Thress KS, Alden RS, Lawrance R, et al
    Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jun 27. pii: JCO667162.
    PubMed     Text format     Abstract available


  63. RUSTHOVEN CG, Doebele RC
    Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jun 13. pii: JCO672410.
    PubMed     Text format     Abstract available


    May 2016
  64. POTTGEN C, Gauler T, Bellendorf A, Guberina M, et al
    Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectabl
    J Clin Oncol. 2016 May 31. pii: JCO655167.
    PubMed     Text format     Abstract available


  65. KAWAGUCHI T, Koh Y, Ando M, Ito N, et al
    Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study.
    J Clin Oncol. 2016 May 9. pii: JCO642322.
    PubMed     Text format     Abstract available


    April 2016
  66. CHAMBERLAIN MC
    Targetable Lung Cancer Brain Metastases: Improved Outcome.
    J Clin Oncol. 2016 Apr 25. pii: JCO669465.
    PubMed     Text format    


  67. COPUR MS, Ramaekers R, Clark D, Norvell M, et al
    Is It Time to Reconsider Prophylactic Cranial Radiation in Non-Small-Cell Lung Cancer?
    J Clin Oncol. 2016 Apr 25. pii: JCO652974.
    PubMed     Text format    


    March 2016
  68. SOLOMON BJ, Cappuzzo F, Felip E, Blackhall FH, et al
    Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
    J Clin Oncol. 2016 Mar 28. pii: JCO635888.
    PubMed     Text format     Abstract available


  69. PRESLEY CJ, Gross CP, Lilenbaum RC
    Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient.
    J Clin Oncol. 2016 Mar 21. pii: JCO659599.
    PubMed     Text format     Abstract available


  70. BAROT N
    You Have Seen Her Before.
    J Clin Oncol. 2016;34:1012.
    PubMed     Text format    


  71. HALABI S, Kelly WK, Ma H, Zhou H, et al
    Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2016 Mar 7. pii: JCO657270.
    PubMed     Text format     Abstract available


  72. AHN JS, Park K
    Reply to Y.H. Kim and M. Mishima.
    J Clin Oncol. 2016;34:768.
    PubMed     Text format    


  73. PETERS S
    Emerging Options After Progression During Crizotinib Therapy.
    J Clin Oncol. 2016;34:643-5.
    PubMed     Text format    


    February 2016
  74. MARTIN LW, D'Cunha J, Wang X, Herzan D, et al
    Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance).
    J Clin Oncol. 2016 Feb 29. pii: JCO634543.
    PubMed     Text format     Abstract available


  75. MELOSKY B, Chu Q, Juergens R, Leighl N, et al
    Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.
    J Clin Oncol. 2016 Feb 16. pii: JCO638049.
    PubMed     Text format     Abstract available


  76. PIETANZA MC
    Using a Population-Based Analysis to Determine the Management and Treatment of Early-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Feb 16. pii: JCO656462.
    PubMed     Text format    


  77. CORRE R, Greillier L, Le Caer H, Audigier-Valette C, et al
    Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
    J Clin Oncol. 2016 Feb 16. pii: JCO635839.
    PubMed     Text format     Abstract available


  78. AHN MJ
    Reply to E. Giovannetti et al.
    J Clin Oncol. 2016;34:512-3.
    PubMed     Text format    


  79. VAN LEEUWEN RW, Peric R, Hussaarts KG, Kienhuis E, et al
    Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Feb 8. pii: JCO652560.
    PubMed     Text format     Abstract available


  80. BRAMBILLA E, Le Teuff G, Marguet S, Lantuejoul S, et al
    Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Feb 1. pii: JCO630970.
    PubMed     Text format     Abstract available


    January 2016
  81. SENAN S, Brade A, Wang LH, Vansteenkiste J, et al
    PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jan 25. pii: JCO648824.
    PubMed     Text format     Abstract available


  82. KUIJPERS W, Oldenburg HS, Wouters MW, Aaronson NK, et al
    Feasibility and preliminary efficacy of an interactive portal for lung cancer patients.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  83. RYAN J, Fetrick A, Ganti AK
    Late-stage lung cancer patient preferences about chemotherapy treatment adverse side effects.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  84. AWAD MM
    Understanding the Pathway: Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jan 19. pii: JCO642777.
    PubMed     Text format    


  85. YANG CJ, Chan DY, Speicher PJ, Gulack BC, et al
    Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jan 19. pii: JCO638171.
    PubMed     Text format     Abstract available


  86. DECATRIS MP, Farrugia D, O'Byrne KJ
    Clinician Perspective on Molecular Profiling of Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jan 11. pii: JCO652040.
    PubMed     Text format    


  87. KIM YH, Mishima M
    Consolidation Chemotherapy After Concurrent Chemoradiotherapy in Patients With Stage III Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jan 11. pii: JCO639393.
    PubMed     Text format    


  88. BEZJAK A, Temin S, Azzoli CG
    Reply to B. Jeremic et al.
    J Clin Oncol. 2016;34:197-8.
    PubMed     Text format    


  89. AWAD MM, Oxnard GR, Jackman DM, Savukoski DO, et al
    MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
    J Clin Oncol. 2016 Jan 4. pii: JCO634600.
    PubMed     Text format     Abstract available


    December 2015
  90. GIOVANNETTI E, Zucali PA, Rolfo C, Assaraf YG, et al
    Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open.
    J Clin Oncol. 2015 Dec 28. pii: JCO642496.
    PubMed     Text format    


  91. MACBETH F, Noble S, Evans J, Ahmed S, et al
    Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial.
    J Clin Oncol. 2015 Dec 23. pii: JCO640268.
    PubMed     Text format     Abstract available


  92. PATEL MI, Wang A, Kapphahn K, Desai M, et al
    Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health Initiative.
    J Clin Oncol. 2015 Dec 23. pii: JCO635789.
    PubMed     Text format     Abstract available


  93. DONINGTON JS
    An Additional Step Toward Personalization of Surgical Care for Early-Stage Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2015 Dec 7. pii: JCO647578.
    PubMed     Text format    


  94. AN MW, Han Y, Meyers JP, Bogaerts J, et al
    Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods.
    J Clin Oncol. 2015;33:4048-57.
    PubMed     Text format     Abstract available


  95. CURLEY BF
    You've Lived a Good Life.
    J Clin Oncol. 2015;33:4118-9.
    PubMed     Text format    


  96. HURWITZ HI, Uppal N, Wagner SA, Bendell JC, et al
    Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
    J Clin Oncol. 2015;33:4039-47.
    PubMed     Text format     Abstract available


    November 2015
  97. SHI W, Dicker AP
    CNS Metastases in Patients With Non-Small-Cell Lung Cancer and ALK Gene Rearrangement.
    J Clin Oncol. 2015 Nov 30. pii: JCO639682.
    PubMed     Text format    


  98. OU SI, Ahn JS, De Petris L, Govindan R, et al
    Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
    J Clin Oncol. 2015 Nov 23. pii: JCO639443.
    PubMed     Text format     Abstract available


  99. JEREMIC B, Cihoric N, Casas F, Gomez-Caamano A, et al
    No Role For Trimodality Therapy and Consolidation Chemotherapy Compared With Concurrent Radiochemotherapy Alone in Stage III Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2015 Nov 16. pii: JCO.2015.63.5037.
    PubMed     Text format    


  100. MELOSKY B, Anderson H, Burkes RL, Chu Q, et al
    Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.
    J Clin Oncol. 2015 Nov 16. pii: JCO.2015.62.3918.
    PubMed     Text format     Abstract available


  101. BIRKBAK NJ, Hiley CT, Swanton C
    Evolutionary Precision Medicine: A Role for Repeat Epidermal Growth Factor Receptor Analysis in ALK-Rearranged Lung Adenocarcinoma?
    J Clin Oncol. 2015;33:3681-3.
    PubMed     Text format    


  102. CAI W, Lin D, Wu C, Li X, et al
    Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
    J Clin Oncol. 2015;33:3701-9.
    PubMed     Text format     Abstract available


  103. MURPHY C, Schwalb H, Berlangieri S, Eek R, et al
    Intraluminal Superior Vena Cava Metastasis in a Patient With Poorly Differentiated Thyroid Carcinoma.
    J Clin Oncol. 2015;33:e119-21.
    PubMed     Text format    


  104. MURPHY DR, Wu L, Thomas EJ, Forjuoh SN, et al
    Electronic Trigger-Based Intervention to Reduce Delays in Diagnostic Evaluation for Cancer: A Cluster Randomized Controlled Trial.
    J Clin Oncol. 2015;33:3560-7.
    PubMed     Text format     Abstract available


  105. CHIOU VL, Burotto M
    Pseudoprogression and Immune-Related Response in Solid Tumors.
    J Clin Oncol. 2015;33:3541-3.
    PubMed     Text format    


  106. GRAZIANO P, de Marinis F, Gori B, Gasbarra R, et al
    EGFR-Driven Behavior and Intrapatient T790M Mutation Heterogeneity of Non-Small-Cell Carcinoma With Squamous Histology.
    J Clin Oncol. 2015;33:e115-8.
    PubMed     Text format    


    September 2015
  107. SANTANA-DAVILA R, Devisetty K, Whittle J
    Reply to D.A. Palma et al and A. Addeo et al.
    J Clin Oncol. 2015;33:2929.
    PubMed     Text format    


  108. GILL BS, Flickinger JC, Beriwal S
    Caveat for Immortal Time Bias in Adjuvant Therapy-Related Population-Based Analyses.
    J Clin Oncol. 2015;33:2931.
    PubMed     Text format    


  109. ROBINSON CG, Patel AP, DeWees T, Morgensztern D, et al
    Reply to C. Le Pechoux et al and B.S. Gill et al.
    J Clin Oncol. 2015;33:2932-3.
    PubMed     Text format    


  110. EBERHARDT WE
    Reply to D.A. Palma et al and A. Addeo et al.
    J Clin Oncol. 2015;33:2929-30.
    PubMed     Text format    


  111. GANDARA DR, Lara PN Jr, Mack PC
    Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap.
    J Clin Oncol. 2015;33:2839-40.
    PubMed     Text format    


  112. UJIIE H, Kadota K, Chaft JE, Buitrago D, et al
    Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.
    J Clin Oncol. 2015;33:2877-84.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: